Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 2
2001 2
2002 2
2003 2
2004 1
2005 2
2006 7
2007 5
2008 2
2009 1
2011 1
2013 3
2015 1
2016 1
2017 1
2018 1
2019 1
2020 3
2021 1
2022 5
2023 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
[Informed consent in radiotherapy care].
Sire C, Ducteil A, Lagrange JL, Maingon P, Lorchel F, Latorzeff I, Hennequin C, Giraud P, Leroy T, Vendrely V, Hannoun-Lévi JM, Chargari C, Pourel N, Elhouat Y, Mazeron JJ, Marchesi V, Huguet F, Monpetit É, Azria D. Sire C, et al. Among authors: lorchel f. Cancer Radiother. 2024 Jun;28(3):290-292. doi: 10.1016/j.canrad.2024.04.001. Epub 2024 Jun 11. Cancer Radiother. 2024. PMID: 38866651 French.
[Ethical stakes in palliative care in radiation oncology].
Haaser T, Constantinides Y, Huguet F, De Crevoisier R, Dejean C, Escande A, Ghannam Y, Lahmi L, Le Tallec P, Lecouillard I, Lorchel F, Thureau S, Lagrange JL; pour la Commission Éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2021 Oct;25(6-7):699-706. doi: 10.1016/j.canrad.2021.07.004. Epub 2021 Aug 13. Cancer Radiother. 2021. PMID: 34400087 Review. French.
[Practical recommendations for breathing-adapted radiotherapy].
Simon L, Giraud P, Dumas JL, Marre D, Dupont S, Varmenot N, Ginestet C, Caron J, Marchesi V, Ferreira I, Lorchel F, Garcia R, Rosenwald JC. Simon L, et al. Among authors: lorchel f. Cancer Radiother. 2007 Jun;11(4):214-24. doi: 10.1016/j.canrad.2007.06.002. Epub 2007 Jul 2. Cancer Radiother. 2007. PMID: 17604206 Review. French.
[Ethical stakes of information in radiation oncology: Thinking the risk and building the therapeutic alliance].
Haaser T, Lahmi L, Osman D, Gesbert C, Cheval V, Constantinides Y, de Crevoisier R, Dejean C, Escande A, Ghannam Y, Lorchel F, Thureau S, Lagrange JL, Durdux C, Huguet F; Commission éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2023 Sep;27(6-7):480-486. doi: 10.1016/j.canrad.2023.06.006. Epub 2023 Aug 10. Cancer Radiother. 2023. PMID: 37573195 Review. French.
Radiation and chemoradiation therapy for esophageal adenocarcinoma.
Bosset JF, Lorchel F, Mantion G, Buffet J, Créhange G, Bosset M, Chaigneau L, Servagi S. Bosset JF, et al. Among authors: lorchel f. J Surg Oncol. 2005 Dec 1;92(3):239-45. doi: 10.1002/jso.20365. J Surg Oncol. 2005. PMID: 16299784 Review.
[Crisis situations: Ethical reflection on prioritization of care access in radiation oncology].
Haaser T, Constantinides Y, Lahmi L, Huguet F, de Crevoisier R, Dejean C, Escande A, Ghannam Y, Le Tallec P, Lorchel F, Mourman V, Thureau S, Lagrange JL; commission Éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2022 Oct;26(6-7):834-840. doi: 10.1016/j.canrad.2022.07.010. Epub 2022 Sep 6. Cancer Radiother. 2022. PMID: 36075833 Review. French.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
45 results